Adocia (ADOCY)
(Delayed Data from OTC)
$11.80 USD
0 (0.00%)
Updated Dec 31, 1969 06:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Adocia [ADOCY]
Reports for Purchase
Showing records 1 - 20 ( 23 total )
Company: Adocia
Industry: Medical - Biomedical and Genetics
Company: Adocia
Industry: Medical - Biomedical and Genetics
M1Pram Shows Even More Potential for Higher BMI Patients; Reiterate Buy, Adjust Target to ?11
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Adocia
Industry: Medical - Biomedical and Genetics
M1Pram Offers Early Proof of Concept; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Adocia
Industry: Medical - Biomedical and Genetics
Company: Adocia
Industry: Medical - Biomedical and Genetics
Announces ?7M in Additional Financing for Obesity Program on 3Q Update; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Adocia
Industry: Medical - Biomedical and Genetics
Progress Across the Pipeline, Especially for BC Lispro in 1H21; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Adocia
Industry: Medical - Biomedical and Genetics
Company: Adocia
Industry: Medical - Biomedical and Genetics
Company: Adocia
Industry: Medical - Biomedical and Genetics
Validated Assets Poised for More Clinical Trials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Adocia
Industry: Medical - Biomedical and Genetics
Takeaways From Our Coverage at the 2021 H.C. Wainwright BioConnect Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Adocia
Industry: Medical - Biomedical and Genetics
Company: Adocia
Industry: Medical - Biomedical and Genetics
Positive BC Lispro Insulin Bridging Study Clears Way For US, EU and Chinese Phase 3 Trials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Adocia
Industry: Medical - Biomedical and Genetics
Adocia Unveils Pancreatic Sem Cell Therapy for T1D at H.C. Wainwright BioConnect Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Adocia
Industry: Medical - Biomedical and Genetics
Adocia Provides Uneventful 3Q Earnings Update; Reiterate Buy, Lower Price Target to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Adocia
Industry: Medical - Biomedical and Genetics
Additional Data in T1D Further Validates Clinical Utility of M1Pram as Adocia Expands Pramlintide Portfolio; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Adocia
Industry: Medical - Biomedical and Genetics
Adocia Announces 1H20 Earnings Prerelease and Progress on M1Pram and BC Insulin; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Adocia
Industry: Medical - Biomedical and Genetics
M1Pram Shows Differentiated Effect on Weight Loss; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Adocia
Industry: Medical - Biomedical and Genetics
M1Pram Shows Positive Phase 1b Data, US Patent Granted, and Additional Studies Planned
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D